NASDAQ:CARA - Cara Therapeutics Stock Price, Forecast & News

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics Inc (NASDAQ:CARA) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.15. The biopharmaceutical company earned $5.79 million during the quarter, compared to the consensus estimate of $5.56 million. Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%. View Cara Therapeutics' Earnings History.

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Cara Therapeutics.

4 analysts have issued 12 month target prices for Cara Therapeutics' shares. Their forecasts range from $30.00 to $39.00. On average, they anticipate Cara Therapeutics' share price to reach $33.80 in the next year. This suggests a possible upside of 90.1% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.

News headlines about CARA stock have trended somewhat negative on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cara Therapeutics earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Cara Therapeutics.

Cara Therapeutics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,850,000 shares, a decline of 9.7% from the January 15th total of 5,370,000 shares. Based on an average daily trading volume, of 729,500 shares, the days-to-cover ratio is currently 6.6 days. Approximately 11.4% of the shares of the company are short sold. View Cara Therapeutics' Current Options Chain.

Some companies that are related to Cara Therapeutics include Deciphera Pharmaceuticals (DCPH), Alkermes (ALKS), Amicus Therapeutics (FOLD), Taro Pharmaceutical Industries (TARO), ChemoCentryx (CCXI), Uniqure (QURE), Insmed (INSM), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Biohaven Pharmaceutical (BHVN), Karuna Therapeutics (KRTX), Epizyme (EPZM), Ra Pharmaceuticals (RARX), Synthorx (THOR) and Turning Point Therapeutics (TPTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Canopy Growth (CGC), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), 22nd Century Group (XXII), Insys Therapeutics (INSY), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH), Novavax (NVAX) and BioMarin Pharmaceutical (BMRN).

Cara Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Farallon Capital Management LLC (5.75%), Chescapmanager LLC (3.25%), State Street Corp (2.50%), Franklin Resources Inc. (1.41%), Pinnacle Associates Ltd. (1.16%) and Bank of America Corp DE (1.05%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics.

CARA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Ladenburg Thalmann Financial Services Inc., Franklin Resources Inc., Exane Derivatives, DekaBank Deutsche Girozentrale and Advisor Group Inc.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Mani Mohindru and Scott Terrillion. View Insider Buying and Selling for Cara Therapeutics.

CARA stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Cypress Capital Management LLC WY, Farallon Capital Management LLC, Pinnacle Associates Ltd., J. Goldman & Co LP, AdvisorShares Investments LLC, State Street Corp and Assenagon Asset Management S.A.. View Insider Buying and Selling for Cara Therapeutics.

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CARA stock can currently be purchased for approximately $17.78.

Cara Therapeutics has a market capitalization of $711.73 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.View Additional Information About Cara Therapeutics.

The official website for Cara Therapeutics is http://www.caratherapeutics.com/.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.